IBEX Limited (IBEX) Q1 2027 Earnings Call Transcript

IBEX reported record Q1 FY2027 revenue of $175.2 million, up 16% year over year, and adjusted EBITDA of $25.2 million, up 29%, with adjusted EBITDA margin expanding 150 basis points to 14.4%. The company raised FY2027 revenue guidance to $720 million–$735 million and adjusted EBITDA guidance to $96 million–$99 million; it also increased planned capex to approximately $30 million to support growth. HealthTech revenue rose 40%, and management cited AI-agent deployments, new client wins and existing-client expansion as growth drivers; quarterly share repurchases totaled approximately 123,000 shares for $4.4 million.

Analysis

The key read-through is not simply stronger demand: IBEX is trying to convert AI from a labor-substitution risk into a customer-acquisition wedge. If AI deployments help win the broader human-support contract, automation could increase wallet share even as it reduces contacts per customer. That is a more durable model than relying on agent-seat growth—but the call gives no standalone AI revenue, gross profit, or retention data, so the claimed economics remain unverified.

Near term, raised guidance and management’s expectation of year-over-year EBITDA improvement each remaining quarter support estimate revisions. The next 1–3 months hinge on converting recent wins into launched, billable work and completing the announced transition of a large client’s traditional CX work by December. A miss could expose how much growth is dependent on a small cohort of recently won contracts. Higher planned capex is consistent with demand but makes utilization and launch timing important; DSO and free-cash-flow conversion deserve monitoring alongside EBITDA.

Over 6–18 months, a growing mix of health tech, digital acquisition, and offshore delivery could support margin expansion. Counterpoint: AI may ultimately reduce human-agent volumes, while competitors can partner for similar tools; current evidence does not establish a lasting moat. The tax-rate normalization also means operating growth may translate less strongly into GAAP EPS than the prior-year comparison suggests.

Contrarian view: skepticism about AI-driven BPO disruption may be too broad if integrated AI-plus-human delivery is winning work from incumbents. But the bullish case may already be reflected in the shares; without current valuation and price data, avoid a price-target-based recommendation.

Key Decisions for Investors

• Consider a measured long in IBEX after checking the post-call share-price reaction and valuation; the earnings and guidance direction are constructive, but do not chase a sharp gap higher without confirming that the implied growth multiple remains reasonable.
• Treat the December client transition and Q2 launch cadence as the main 1–3 month catalysts. Add only if launches convert to reported revenue and management sustains quarterly year-over-year EBITDA improvement.
• Track AI-specific revenue or contract disclosure, client-level expansion, and human-agent volumes. If AI adoption rises while total client spend or IBEX revenue per client falls, the land-and-expand thesis is weakening.
• Falsification / risk controls: reassess on a guidance cut, failure to deliver year-over-year EBITDA improvement in a remaining FY27 quarter, material deterioration in DSO or cash conversion, or evidence that the December transition is delayed or not economically additive.